Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2025 | 816 | 1.800 |
Why?
|
| Methotrexate | 8 | 2025 | 351 | 1.660 |
Why?
|
| Rhabdomyosarcoma | 3 | 2025 | 214 | 1.070 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2025 | 195 | 0.840 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 64 | 0.810 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.700 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 26 | 0.690 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1683 | 0.500 |
Why?
|
| Bayes Theorem | 3 | 2023 | 309 | 0.380 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 137 | 0.360 |
Why?
|
| Child | 20 | 2025 | 25823 | 0.360 |
Why?
|
| Adolescent | 13 | 2025 | 20552 | 0.240 |
Why?
|
| Prognosis | 5 | 2025 | 5009 | 0.230 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.220 |
Why?
|
| Child, Preschool | 9 | 2025 | 14853 | 0.220 |
Why?
|
| Creatinine | 2 | 2023 | 400 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.220 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2024 | 54 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 1451 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2025 | 131 | 0.210 |
Why?
|
| Constipation | 1 | 2024 | 128 | 0.210 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 54 | 0.200 |
Why?
|
| Health Information Systems | 1 | 2022 | 32 | 0.190 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2022 | 22 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 57 | 0.190 |
Why?
|
| Warfarin | 1 | 2023 | 127 | 0.190 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 194 | 0.180 |
Why?
|
| Infant | 7 | 2025 | 13192 | 0.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 52 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 67 | 0.180 |
Why?
|
| Wilms Tumor | 1 | 2023 | 118 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2025 | 361 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 1303 | 0.180 |
Why?
|
| Humans | 22 | 2025 | 132336 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1347 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2022 | 241 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2023 | 517 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 342 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17363 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 453 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2024 | 698 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 121 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 253 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1357 | 0.140 |
Why?
|
| Risk Factors | 2 | 2023 | 10910 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 206 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 197 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1192 | 0.120 |
Why?
|
| Male | 10 | 2025 | 65054 | 0.120 |
Why?
|
| Female | 10 | 2025 | 70788 | 0.110 |
Why?
|
| Age Factors | 1 | 2021 | 2931 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 540 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 529 | 0.110 |
Why?
|
| Malawi | 2 | 2025 | 426 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5405 | 0.090 |
Why?
|
| Mutation | 1 | 2025 | 6248 | 0.090 |
Why?
|
| Young Adult | 4 | 2025 | 9945 | 0.080 |
Why?
|
| Anticoagulants | 2 | 2024 | 607 | 0.080 |
Why?
|
| Survival Rate | 2 | 2025 | 2187 | 0.070 |
Why?
|
| Incidence | 2 | 2024 | 3361 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2024 | 170 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 200 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 43 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 108 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 67 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 85 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 47 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 322 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 105 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 180 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 346 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1458 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 989 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1229 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 618 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1297 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 573 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1367 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 483 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 215 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 216 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5150 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1964 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1125 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 6455 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3853 | 0.020 |
Why?
|
| United States | 1 | 2022 | 11628 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 13016 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8566 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 31618 | 0.010 |
Why?
|